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Abstract : The outcomes of treatment for pain disorder are generally disap-
pointing : symptoms are poorly controlled, they are seldom managed by 
experts, and they are often long standing.  The aim of the present study was 
to compare the therapeutic effectiveness of paroxetine and milnacipran for 
outpatients with pain disorder.  The study was performed on 43 consecutive 
outpatients with pain disorder diagnosed according to DSM-IV-TR criteria.  
Patients were treated with either antidepressant for 8 weeks.  Pain was self-
assessed using the Short-Form McGill Pain Questionnaire （SF-MPQ）, the total 
Pain Rating Index （t-PRI）, Present Pain Intensity （PPI）, and visual analogue 
scale （VAS）.  In addition, pain was evaluated objectively using Pain Vision 
（a machine devised by NIPRO for semiquantitative measurements）.  Possible 
depressive symptoms were rated on the Hamilton Depression Scale （HAM-
D） and the Zung Self-rating Depression Scale （SDS）.  Although VAS scores 
decreased signicantly over the course of the 8-week trial in both the parox-
etine- and milnacipran-treated groups （from 6.6 ± 2.3 to 4.8 ± 3.0 ［P ＝ 0.01］ 
and from 7.5 ± 2.4 to 5.4 ± 3.3 ［P＝ 0.03］, respectively）, the t-PRI decreased 
only in the paroxetine group （from 13.9 ± 10.1 to 7.6 ± 7.5 ; P＝ 0.01）.  The 
Pain Vision indicated a tendency for decreased pain in both groups, with 
no significant differences between them.  There were no significant changes 
in the SDS in either group, but the HAM-D decreased significantly in the 
milnacipran-treated group （from 7.8 ± 4.0 to 6.7 ± 3.9 ; P＝ 0.04）.  The results 
of the present study suggest that both paroxetine （a selective serotonin re-
uptake inhibitor） and milnacipran （a selective serotonin–noradrenaline re-
uptake inhibitor） may decrease pain in individuals with pain disorder.
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Introduction
　Many people suffer from various types of chronic pain.  Despite the heavy social burden, 
the outcomes of treatment for pain are disappointing : symptoms are poorly controlled, they 
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are seldom managed by experts, and they are often long standing.  In addition, the risk of 
suicide is increased in patients with chronic pain 1）.  Many different somatic and psychiatric 
diseases may cause chronic pain.  The latter include depression and somatization, delusional, 
and anxiety disorders.  The denition of pain adopted by the International Association for 
the Study of Pain （IASP） is essentially that pain is an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage 2）.  From this viewpoint, pain is an emotional experience, and it is easy to under-
stand why chronic pain coexists with psychiatric diseases and mood changes.
　There are no therapeutic guidelines for the treatment of pain disorder.  In general, anal-
gesics have limited effectiveness and may lead to drug abuse and/or dependence.  Therefore, 
tricyclic antidepressants （TCAs） are often used to treat pain disorders.  The guidelines of 
the American Society of Anesthesiologists 3） recommend the use of TCAs and selective 
serotonin-noradrenaline re-uptake inhibitors （SNRIs） for the relief of chronic pain of varying 
etiology.  It is unclear whether there are any benets of using selective serotonin reuptake 
inhibitors （SSRIs） and benzodiazepines for the treatment of diabetic neuropathy and 
chronic pain.  Although previous studies have reported that dual-action antidepressants with 
serotonergic and noradrenergic effects, such as TCAs and SNRIs, are more effective than 
single-action antidepressants, such as SSRIs, for pain relief 4-8）, recent studies have also dem-
onstrated the effectiveness of SSRIs in relieving pain 9，10）.  Aragona et al compared the SSRI 
citalopram with the noradrenaline re-uptake inhibitor reboxetine in outpatients with pain dis-
order 9） and found that citalopram has a moderate pain-relieving effect for patients with pain 
disorder that appears to be independent of changes in depressive scores.  Similarly, Inoue 
reported that the SSRI paroxetine was a strong blocker of P2X4 receptors 10）, and P2X4 
receptor antagonists may have excellent therapeutic potential in the treatment of neuropathic 
pain.  Thus, the question as to whether there are any differences in efcacy between SSRIs 
and SNRIs remains unresolved.
　In the clinical setting, pain is usually evaluated subjectively, such as by the McGill Pain 
Questionnaire （MPQ）11） or the Short-Form McGill Pain Questionnaire （SF-MPQ）12）. 
However, because of psychological reasons, it is difcult to evaluate pain accurately using 
subjective measures.  Accordingly, objective or quantied evaluation of pain is warranted. 
The Pain Vision is a machine produced by NIPRO （Pain Vision PS-2100） that has been 
developed specically to provide a semiquantitative measure of pain.
　The aim of the present study was to compare the therapeutic effectiveness of paroxetine 
and milnacipran for outpatients with pain disorder.  Pain was evaluated both subjectively 
（SF-MPQ） and objectively （Pain Vision）.
Materials and Methods
Study subjects
　The study subjects were selected from patients （20 years or older） who regularly attended 
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the psychiatry clinic at Showa University East Hospital.  Exclusion criteria included preg-
nancy, thyroid gland malfunction, glaucoma, and urinary retention.
　All participants were examined by a psychiatrist and had to fulll the Diagnostic and 
Statistical Manual of Mental Disorders （fourth edition, text revision ; DSM-IV-TR）13） criteria 
for pain disorder, namely pain disorder associated with psychological factors or pain disorder 
associated with psychological factors and general physical diseases.
Study design
　Patients were allowed to continue analgesic and anti-inammatory medications at the same 
dose during the pretreatment period, although they were not allowed to increase medication 
doses during the treatment period.  Patients were allowed to take low doses of benzodi-
azepines for sleep disturbances, but were not allowed to take anti-anxiety agents for pain 
relief.
　Patients were randomly assigned to receive either paroxetine or milnacipran for 8 weeks 
using random tables with the first （and original） generator 14）.  The doses of paroxetine 
ranged from 10 to 40 mg/day, whereas those of milnacipran ranged from 50 to 150 mg/day. 
The initial doses of paroxetine and milnacipran were 10 and 50 mg, respectively, although 
these doses were suitably adjusted during the treatment period.
Assessments
　Patients were evaluated at baseline and then again after 4 and 8 weeks treatment.  Pain 
was self-assessed using the SF-MPQ, the total Pain Rating Index （t-PRI）, Present Pain 
Intensity （PPI）, and using a visual analogue scale （VAS）.  In addition, pain was evaluated 
objectively with the Pain Vision.  By using electrode pads attached to the subject’s arm and 
measuring the current perception threshold and the current corresponding to the pain, the 
Pain Vision enables the magnitude of the pain to be semiquantied.  The index relating to 
the magnitude of pain is based on the Pain Index and Pain Frequency.  Possible depressive 
symptoms were rated in each of the subjects using the Hamilton Depression Scale （HAM-
D） and Zung Self-rating Depression Scale （SDS）.
　All adverse events were recorded : those noted by psychiatrists during the treatment peri-
od and those of which the subjects complained.  Newly expressed symptoms and symptoms 
that worsened during the treatment period were recorded as adverse events.  If adverse 
events occurred, we recorded the symptoms, the severity of the symptoms, and the number 
of manifestations and took appropriate action.
　The present study was performed in accordance with ethical guidelines and principles for 
clinical trials based on the Declaration of Helsinki.  The study, including the risks and ben-
ets of participation, was fully explained to patients in a written document.  Before enrolling 
in the study, patients were required to provide written informed consent.
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Statistical analysis
　All data were analyzed using SAS 9.1.3Ⓡ and managed using PROMASYSⓇ.  Efcacy 
measures were analyzed in the intent-to-treat population, which was defined as patients 
who underwent the randomization process and took at least one dose of paroxetine or 
milnacipran and had at least one post-baseline efcacy evaluation.  Safety parameters were 
analyzed for all patients enrolled in the study who took at least one dose of study medica-
tion.  If patients dropped out prematurely from the study or discontinued treatment, the last 
evaluation score of the day was treated as an evaluation score at 8 weeks using the Last 
Observation Carried Forward （LOCF） method.
　Differences in demographic variables and clinical characteristics between the two treatment 
groups were assessed using Fisher’s exact test for categorical variables and the t-test for con-
tinuous variables.  The t-test was used to evaluate differences between baseline and the last 
evaluation score for the primary outcome variables （t-PRI, VAS, PPI） and the secondary 
outcome variables （Pain Vision, HAM-D, SDS） within each group.  Two-sided P＜ 0.05 was 
considered signicant.  Unless indicated otherwise, data are presented as the mean ± SD.
Results
　In all, 43 patients, enrolled in the trial, were randomly divided into two groups.  Twenty-
one patients were assigned to receive paroxetine and 22 were assigned to receive milnacip-
ran.  Eighteen patients were unable to complete the treatment period.  Four patients were 
lost to follow-up at 4 weeks （one in the paroxetine group and three in the milnacipran 
group）.  Twelve patients （ve in the paroxetine group and seven in the milnacipran group） 
dropped out because of adverse effects ; another two patients in the milnacipran group 
dropped out due to inefcacy of the medication.  Accordingly, at the end of the treatment 
period, there were 15 patients remaining in the paroxetine group （10 men ; mean age 55.2
± 16.3 years） and 10 patients remaining in the milnacipran group （four men ; mean age 
49.9 ± 13.6 years）.  The demographic characteristics of all study subjects are given in Table 1.
　There was a signicant decrease in t-PRI in the paroxetine-treated group at the end of 
the 8-week treatment period compared with baseline （7.6 ± 7.5 vs. 13.9 ± 10.1, respectively ; 
P ＝ 0.01）, but no signicant change in t-PRI in the milnacipran-treated group （7.9 ± 4.6 
vs. 13.0 ± 9.1, respectively ; P＝ 0.11 ; Fig. 1 ; Table 2）.  Pain scores on the VAS decreased 
signicantly in both groups （from 6.6 ± 2.3 to 4.8 ± 3.0 in the paroxetine-treated group ［P＝
0.01］; and from 7.5 ± 2.4 to 5.4 ± 3.3 in the milnacipran-treated group ［P＝ 0.03］）.  There 
was a tendency for PPI to decrease in both groups, but the differences failed to reach statis-
tical signicance （from 2.7 ± 1.2 to 1.9 ± 1.3 in the paroxetine-treated group ［P＝ 0.10］; and 
from 3.0 ± 1.3 to 2.1 ± 0.9 in the milnacipran-treated group ［P ＝ 0.07］）.  When pain was 
evaluated semiquantitatively using the Pain Vision, no signicant differences were observed 
between the two groups, although there were tendencies for decreases in the Pain Index and 
Pain Frequency in both groups following treatment.  There were no signicant changes in 
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SDS in either group （from 44.4 ± 13.9 to 43.9 ± 12.1 in the paroxetine-treated group ［P＝
0.86］; and from 45.2 ± 11.6 to 40.5 ± 9.7 in the milnacipran-treated group ［P＝ 0.11］）, but 
HAM-D decreased signicantly after treatment in the milnacipran-treated group （from 7.8 ±
4.0 to 6.7 ± 3.9 ; P＝ 0.04 ; Table 2）.
　Seven patients （one in the paroxetine group and six in the milnacipran group） withdrew 
from treatment before the rst outcome assessment.  Eleven patients （ve in the paroxetine 
group and six in the milnacipran group） withdrew from the study before the second out-
come measurement.
　Table 3 lists adverse events.  Most adverse events were mild to moderate in severity, and 
no patient experienced any serious adverse event.  The most common adverse events were 
nausea, somnolence, and constipation.
Discussion
　To the best of our knowledge, the present study is the rst to compare an SSRI with 
Table 1.  Demographic characteristics
Characteristic Paroxetine（N＝ 15） Milnacipran（N＝ 10） p value
Gender 0.24
Male, N（%） 10（66.7）  4（40.0）
Female, N（%）  5（33.3）  6（60.0）
Age（years） 55.2 ± 16.3 49.9 ± 13.6 0.41
Range 32-79 27-68
Fig. 1.  Significant decreases were seen in the total Pain Rating Index 
（t-PRI） in the paroxetine-treated group over the course of the 
8-week trial （from 13.9 ± 10.1 to 7.6 ± 7.5 ; P ＝ 0.01）, but there 
was no significant change in the milnacipran-treated group （from 
13.0 ± 9.1 to 7.9 ± 4.6 ; P＝ 0.11）.  Data are the mean ± SD.  P＜
0.05 compared with baseline values.
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an SNRI for patients with pain disorder in the psychiatric setting.  All participants in the 
present study were examined by a board psychiatrist and had to fulll DSM-IV-TR criteria 
for pain disorder.  In addition, pain was evaluated not only subjectively using the SF-MPQ 
and VAS, but also objectively using the Pain Vision.  The results show that both paroxetine 
and milnacipran are benecial in reducing pain.  Although the VAS scores were signicantly 
decreased over the course of the 8-week trial in both groups, t-PRI only decreased signi-
cantly in the paroxetine-treated group.
　Previous studies demonstrated that antidepressants that affect noradrenaline, such as 
TCAs and SNRIs, are more effective pain relievers than single-action serotonergic anti-
Table 2.  Inter-group comparison : change from baseline at the final visit
Scale Paroxetine（N＝ 15） p value Milnacipran（N＝ 10） p value p value
Baseline Final visit Change
 from baseline
Baseline Final visit Change
 from baseline
SF-MPQ
t-PRI 13.9 ± 10.1 7.6 ± 7.5 -6.3 ± 7.6 0.01 13.0 ± 9.1  7.9 ± 4.6 -5.1 ± 9.2 0.11 0.73
VAS 6.6 ± 2.3 4.8 ± 3.0 -1.8 ± 2.2 0.01  7.5 ± 2.4  5.4 ± 3.3 -2.1 ± 2.6 0.03 0.78
PPI 2.7 ± 1.2 1.9 ± 1.3 -0.7 ± 1.6 0.1  3.0 ± 1.3  2.1 ± 0.9 -0.9 ± 1.4 0.07 0.79
HAM-D 7.0 ± 3.1 5.4 ± 3.5 -1.6 ± 3.1 0.07  7.8 ± 4.0  6.7 ± 3.9 -1.1 ± 1.4 0.04 0.64
SDS 44.4 ± 13.9 43.9 ± 12.1 -0.5 ± 10.3 0.86 45.2 ± 11.6 40.5 ± 9.7 -4.7 ± 8.5 0.11 0.29
Pain Vision
Pain Index 3.5 ± 3.0 2.3 ± 1.3 -1.2 ± 2.5 0.07  5.7 ± 3.5  4.3 ± 3.5 -1.4 ± 2.2 0.08 0.88
Pain Frequency 　251.3± 298.8
　126.9
± 132.6
-124.4
± 248.1 0.07
　471.4
± 353.3
　332.5
± 346.2
　　-138.9
± 224.4 0.08 0.88
SF-MPQ, Short-Form McGill Pain Questionnaire ; t-PRI, total Pain Rating Index ; VAS, Visual Analogue Scale ; 
PPI, Present Pain Intensity ; HAM-D, Hamilton Depression Scale ; SDS, ZungSelf-rating Depression Scale. All data 
are expressed as mean and std. dev.
Table 3.  Adverse events 
Event Paroxetine（N＝ 15）
N（%）
Milnacipran（N＝ 10）
N（%）
Somnolence 5（33.3） 1（0.1）
Nausea 1（0.07） 5（50）
Constipation 0 6（60）
Giddy feeling 2（13.3） 1（10）
Residual urine 0 3（30）
Palpitation 0 2（20）
Fatigue 2（13.3） 0
Headache 1（0.07） 1（10）
Insomnia 1（0.07） 1（10）
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depressants 4-8）.  It has also been reported that SSRIs are less effective than TCAs and 
monoamine oxidase inhibitors （MAOIs） for the treatment of physical symptoms associated 
with depression 15）.  There is more evidence supporting the alleviation of pain by dual-action 
antidepressants than single-action serotonergic antidepressants.
　However, in the present study, paroxetine was as effective as milnacipran.  This may be 
due, in part, to the fact that paroxetine is a strong blocker of P2X4 receptors 10）.  Activated 
microglia expresses P2X4 receptors after nerve injury, and this upregulation of P2X4 recep-
tors results in the release of brain-derived neurotrophic factor, a key molecule in neuropath-
ic pain.  P2X4 receptor antagonists may be candidate therapeutic drugs for the treatment of 
neuropathic pain.  A recent study has suggested that citalopram, another SSRI, may have a 
moderate analgesic effect in pain disorders, which has clinical implications for those patients 
who are intolerant of TCAs 9）.  Further studies are warranted to determine the pain-relieving 
effects of individual SSRIs.
　Here, both paroxetine and milnacipran effectively ameliorated pain, but the mechanisms 
of action of each drug may be different.  Although the SDS remained unchanged in both 
groups, the HAM-D decreased significantly after 8 weeks of treatment with milnacipran 
only, suggesting that milnacipran may have improved both pain and mood.  Some stud-
ies have reported that antidepressants exert their analgesic and antidepressant effects 
independently 9，16）.  Because no rm conclusions can be reached on the basis of the results 
of the present study, future studies are needed to clarify whether the antidepressant and 
pain-relieving effects of the SSRIs and SNRIs are independent of each other.
　There are several limitations to the present study.  First, the sample size was small and 
the drop-out rate was high.  Generally, high drop-out rates are common for pharmacological 
trials of somatoform disorders 17） because patients with somatization disorders, including pain 
disorders, are the most difcult to treat, with the conditions being largely treatment resistant. 
Further studies with a larger sample are needed to conrm the therapeutic effectiveness of 
paroxetine and milnacipran for pain disorder.  Second, the dose of antidepressants used in 
the present study was not xed over the course of the 8-week trial, and the exible dosing 
of paroxetine and milnacipran may have affected the therapeutic effectiveness of the treat-
ment regimen.  Third, the present study focused only on paroxetine and milnacipran.  There 
are many drugs in both the SSRI and SNRI categories, such as sertraline and s-citalopram 
（SSRIs） and duloxetine and venlafaxine （SNRIs）, and it is not clear whether these drugs are 
as effective as paroxetine and milnacipran.  This issue should be explored in future studies.
　In conclusion, the present study is the rst to compare the therapeutic effectiveness of 
paroxetine and milnacipran for pain disorder in a psychiatric setting.  The main finding 
of the study is that both paroxetine and milnacipran are benecial in reducing pain.  Sig-
nicant decreases were seen in t-PRI in the paroxetine group and in VAS scores in both 
groups during the trial.  In contrast with previous studies, paroxetine, a single-action seroto-
nergic drug, had the same pain-relieving effect as milnacipran, a dual-action serotonergic and 
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noradrenergic drug.  Despite the limitations of the present study, the results indicate that 
both the SSRI and SNRI could reduce pain in individuals with pain disorder.
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